Head and neck squamous cell carcinoma (HNSCC), the seventh most prevalent cancer globally, originates from the mucosal epithelium of the oral cavity, pharynx, and larynx. Traditional risk factors like ...

Knowledge of the association between human papillomavirus (HPV) and oropharyngeal squamous cell carcinoma (OPSCC) is poor and ...

Enver Cagri Izgu, from the School of Arts and Sciences at Rutgers-New Brunswick, and his team will use a nearly $2 million ...

The US Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are ...

The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

L1-blocking antibody is now approved for metastatic or locally advanced cutaneous SCC in adults who are not candidates for curative surgery or curative radiation.

FDA approved for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma that is not ...

Checkpoint Therapeutics' Unloxcyt wins FDA approval for advanced cSCC, marking the company's entry into the U.S. market, valued over $1 billion annually.

The FDA has approved cosibelimab under the brand name Unloxcyt for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC that’s not curable by surgery or ...

Checkpoint Therapeutics’ stock has seen a remarkable +60.26% year-to-date increase, far surpassing the S&P 500’s YTD performance of +26.86%. This highlights how well Checkpoint is positioning itself ...

A year after manufacturing issues resulted in a complete response letter for cosibelimab, the U.S. FDA approved Checkpoint Therapeutics Inc.’s drug, branded Unloxcyt, as the first anti-PD-L1 antibody ...

A multi-institutional clinical trial led by the University of Navarra, Spain, found that blocking growth differentiation ...